Faculty Opinions recommendation of Human parvovirus 4 in Brazilian patients with haemophilia, beta-thalassaemia major and volunteer blood donors.

2017 ◽  
Author(s):  
Paul Klenerman
Keyword(s):  
Blood Donors ◽  
Thalassaemia Major ◽  
Beta Thalassaemia

Human parvovirus 4 in Brazilian patients with haemophilia, beta-thalassaemia major and volunteer blood donors

Haemophilia ◽  
2014 ◽  
Vol 21 (1) ◽  
pp. e86-e88 ◽  
Author(s):  
S. N. Slavov ◽  
S. Kashima ◽  
M. C. Rocha-Junior ◽  
A. C. Silva-Pinto ◽  
L. C. Oliveira ◽  
...  
Keyword(s):  
Blood Donors ◽  
Thalassaemia Major ◽  
Beta Thalassaemia

Reproductive health issues in female patients with beta-thalassaemia major: a narrative literature review

2020 ◽  
Vol 40 (7) ◽  
pp. 902-911 ◽  
Author(s):  
Malihe Nourollahpour Shiadeh ◽  
Elena Cassinerio ◽  
Maryam Modarres ◽  
Armin Zareiyan ◽  
Zeinab Hamzehgardeshi ◽  
...  
Keyword(s):  
Reproductive Health ◽  
Literature Review ◽  
Thalassaemia Major ◽  
Health Issues ◽  
Female Patients ◽  
Beta Thalassaemia ◽  
Narrative Literature ◽  
Narrative Literature Review

Porphyria cutanea tarda and beta-thalassaemia major: causal or casual?

2010 ◽  
Vol 24 (10) ◽  
pp. 1242-1243 ◽  
Author(s):  
P Papadantonakis ◽  
O Neofotistou ◽  
A Vasiliadi ◽  
A Skoutelis ◽  
A Tsatsakis ◽  
...  
Keyword(s):  
Porphyria Cutanea Tarda ◽  
Thalassaemia Major ◽  
Beta Thalassaemia

scholarly journals Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series

2016 ◽  
Vol 9 (1) ◽  
pp. e2017004 ◽  
Author(s):  
Shahrzad Zonoozi
Keyword(s):  
Diabetes Mellitus ◽  
Case Series ◽  
Close Monitoring ◽  
Thalassaemia Major ◽  
Efficacy And Safety ◽  
Antidiabetic Agent ◽  
Retrospective Case ◽  
Beta Thalassaemia ◽  
Equivalent Reduction

Sitagliptin, a modern antidiabetic agent which is weight neutral and associated with low rate of hypoglycaemias, is being increasingly used in type 2 diabetes mellitus (DM). However there is paucity of data about its efficacy and safety in beta-thalassaemia major (β-TM).This retrospective case series of five patients (mean age of 45 years) is the first study evaluating the use of sitagliptin in patients with β-TM and DM.Four patients responded well to sitagliptin, as evidenced by decrease in fructosamine by 77 and 96µmol/L (equivalent reduction in HbA1c of 1.5% and 1.9%) observed in two patients and reduction in the frequency of hypoglycaemia without worsening glycaemic control in two others. One patient did not respond to sitagliptin. No patients reported significant side effects.This study provides evidence that sitagliptin may be considered, with caution, for use in patients with β-TM and DM, under the close monitoring of a Diabetologist.

scholarly journals Hydroxyurea appears beneficial in patients with beta-thalassaemia major and intermedia

2007 ◽  
pp. 78 ◽  
Author(s):  
S. F.S.A. Abdul Wahid ◽  
Rozilaila Rahmat ◽  
Shamsul Azhar ◽  
Noor H. Hussin ◽  
Cheong S. Keng
Keyword(s):  
Thalassaemia Major ◽  
Beta Thalassaemia

scholarly journals Clinical Pharmacist-Provided Services In Iron-Overloaded Beta-Thalassaemia Major Children: A New Insight Into Patient Care

2017 ◽  
Vol 120 (4) ◽  
pp. 354-359 ◽  
Author(s):  
Salma M. Bahnasawy ◽  
Lamia M. El Wakeel ◽  
Nagham El Beblawy ◽  
Manal El-Hamamsy
Keyword(s):  
Patient Care ◽  
Clinical Pharmacist ◽  
Thalassaemia Major ◽  
Beta Thalassaemia ◽  
Insight Into
Sign in / Sign up

Export Citation Format

Share Document